A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Trial ID # NCT02446600; NRG-GY004
Phase III
Drug Class DNA Damage Repair Pathway Inhibitors: PARP
Drug Name Olaparib
Alternate Drug Names Lynparza, AZD2281
Drugs in Trial Carboplatin, Cediranib, Gemcitabine, Liposomal doxorubicin, Olaparib, Paclitaxel
Eligible Participant

Platinum sensitive high grade serous or endometrioid ovarian cancer or germline BRCA1/2-mutated ovarian cancer, no prior PARP inhibitor
Patients Enrolled

565, median 1 prior therapy
Therapy Setting

Recurrence
Study Design

Open-Label, Randomized
Endpoints

ORR, PFS, OS, evaluated per RECIST
Efficacy

Ola+Ced (n=189) vs Ola (n=189) vs Treatment of Physician's Choice (TPC) (CarboPt+Gem (27%)/PLD (48%)/Pac (25%)) (n=187):

ORR: 69.4 vs 52.4 vs 71.3%
PFS: 10.4 vs 8.2 vs 10.3 months, HR: 0.86 (0.66-1.11, p=0.077); HR: 1.20 (0.93-1.54)
OS: 30.5 vs 29.2 vs 31.3 months

Exploratory analysis, gBRCA status:
gBRCA MUT: ORR: 89 vs 90 vs 71%; PFS: 18.0 vs 12.7 vs 10.5 months, HR: 0.55 (0.32-0.94); HR: 0.63 (0.37-1.07)
gBRCA WT: ORR: 64 vs 40 vs 72%; PFS: 8.9 vs 6.6 vs 9.7 months, HR: 0.97 (0.73-1.30); HR: 1.41 (1.07-1.81)
Clinically Significant Adverse Events

Ola+Ced vs Ola vs TPC:
Serious AE:
Grade 3-4 AE: neutropenia (3.8 vs 1.6 vs 31.8%), anemia (5.5 vs.15.0 vs 13.8%), thrombocytopenia (1.6 vs 1.0 vs 15.0%), leukopenia (1.1 vs 1.1 vs 14.4%), fatigue (17.5 vs 7.0 vs 1.8%), diarrhea (13.7 vs 1.0 vs 1.8%), hypertension (31.7 vs 5.3 vs 1.8%)
Conclusion

Cediranib+olaparib has similar activity to standard of care in relapsed platinum sensitive ovarian cancer but does not improve PFS
Reference

Lui JF et al. A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer. J Clin Oncol (2020) 38: (suppl; abstr 6003)
https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.6003